论文部分内容阅读
报道了五年间收治的老年急性非淋巴细胞白血病（ＡＮＬＬ）２１例，采用ＤＡ（ＶＰ１６）与ＨＡ（ＶＰ１６）联合化疗，依据不同剂量，将其分为二组，二组总有效率为６６．６％。其中中等剂量组１４例，８例ＣＲ，平均生存时间为２６７天；２例（１８％）ＰＲ：小剂量组７例，２例（２８．５％）ＣＲ，２例（２８．５％）ＰＲ；结果提示：对老年白血病患者治疗应个体化，一般情况好者应在强有力支持治疗情况下采用中等剂量的化疗，相反宜小剂量化疗
In the past five years, 21 cases of acute non-lymphoblastic leukemia (ANLL) were treated and DA (VP16) and HA (VP16) combined chemotherapy were used. According to different doses, they were divided into two groups. The total effective rate was 66. 6%. In the medium-dose group, 14 cases, 8 cases of CR, the average survival time was 267 days; 2 cases (18%) PR: 7 cases of small-dose group, 2 cases (28.5%) CR, 2 cases (28.5%) PR; Results suggest: The treatment of elderly patients with leukemia should be individualized, generally good condition should be in the case of strong support for treatment with moderate doses of chemotherapy, the contrary should be a small dose of chemotherapy